Replies to post #115840 on Biotech Values

[DewDiligence]

An unusually candid statement for a biotech executive (from the same interview):

The reason we are talking about once weekly is a competitive issue rather than a compliance issue… For defensive reasons we're going to develop it. We don't want to get caught flat-footed.

I tend to agree with Sorenson that weekly administration per se is not a significant benefit in compliance. For Byetta/Bydureon specifically, I’ve long thought that reduced dosing frequency was offset or even outweighed by the kind of needle that has to be used to administer Bydureon.

[DewDiligence]

CHMP approves Bydureon:

http://finance.yahoo.com/news/BYDUREON-Recommended-for-prnews-4067637847.html?x=0&.v=1

The approval will be rubber-stamped by the EU Commission in 2-3 months.

[DewDiligence]

Analogs comprised 72% of NVO’s overall insulin sales in 1Q11, the highest proportion ever.

[DewDiligence]

NVO held its Investor Day webcast yesterday—lots of interesting slides on the diabetes market, especially as it pertains to The Global Demographic Tailwind:

http://www.novonordisk.com/investors/download-centre/default.asp?Year=2011

10% of adults in China are diabetic (#msg-48221898), so there’s a really big upside here for somebody.